SUBSCRIBE: eNewsletter
A mother brought her 7-year-old boy to the eye doctor after he complained for several months about increasing photophobia during outdoor activities like soccer practice and playground outings. She also noticed that he had been thirstier than usual during his soccer games, but wasn’t sweating as much as he usually did. During the slit lamp exam, the doctor noted crystals throughout his cornea and conjunctiva. What's your diagnosis?
Postmenopausal women who participate in vigorous physical activity have a lower risk of total and hip fractures, but higher knee fracture risk, say researchers recently writing in JAMA Network Open.
In this slideshow, we review 10 new drugs or new indications for diabetes and other endocrine conditions.
A JAMA study finds that treating elderly patients who have subclinical hypothyroidism does not improve hypothyroid symptoms or fatigue.
A literature review published in JAMA Internal Medicine finds that many medical tests are overused and overtreatment is common and potentially harmful.
In this month's "Endocrine Feedback" column, Dr. Melissa Young explores how her career has evolved over the years and questions what the future may hold.
A 58-year-old man with a history of diabetes mellitus type 1 went to the urgent care after he awoke one morning and noticed the bottom of his foot near his toes felt funny. When he looked at the area, he realized that a bulla had formed on the bottom of his foot overnight. He hadn’t injured or cut the foot or leg recently, and he felt in good health otherwise. What's your diagnosis?
Researchers writing in the New England Journal of Medicine report that a combination treatment of ticagrelor and aspirin leads to improved cardiovascular disease outcomes in patients with stable coronary artery disease and diabetes mellitus.
A comprehensive systematic review and meta-analysis of 36 randomized clinical trials shows that using activity trackers produces some health benefit, but primarily when combined with coaching.
The type 2 diabetes drug dapagliflozin reduces the risk for worsening heart failure or death from cardiovascular disease among individuals with heart failure and reduced ejection fraction, whether or not they have diabetes, shows a study published in the New England Journal of Medicine.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
